Adult RSV Clinical Trial

OVERVIEW

RSV is a common respiratory virus that infects the lungs and breathing passages. People most frequently associate RSV with the risk it brings to young children, but not many know the high risk it poses for older adults.

INVESTIGATIONAL TREATMENT

There are currently no approved treatments or vaccines for RSV. Moderna is sponsoring a clinical trial for mRNA-1345, an investigational vaccine. Moderna is studying this vaccine to understand whether it can help your body’s immune system protect against RSV.

WHAT’S INVOLVED?

The total length of participation in this clinical trial is approximately 2 years (25 months). It includes up to 8 trial visits and 20 brief communications (via telephone).

Clinical trial volunteers will have a screening visit to check whether they are eligible to participate. If they are eligible and choose to participate, they will have 7 more trial visits over the next 2 years
Clinical trial participants will be given one injection in the upper arm
Each clinical trial participant has a 50% chance of receiving the investigational vaccine and a 50% chance of receiving the placebo—like flipping a coin

Reimbursement for travel and your time will be provided, and all study doctor visits will be free of charge.

ELIGIBILITY

60 years of age or older
In good health. Ccertain chronic diseases such as heart failure and chronic obstructive pulmonary disease may be permissible.
Primarily responsible for self-care (do not require a caretaker)
Based in Brisbane

PRINCIPAL INVESTIGATOR

Dr Ken Koh (GP)

CONTACT US

Please contact Holdsworth House Research to register your interest:
Phone: 07 3894 0794 (Brisbane)
Email: studies@holdsworthhouse.com.au
Or enter your details here to request more information.

ConquerRSV Trial - Based in Brisbane

Contact Details